Presentation of Qa-1 restricted peptides during homeostasis and viral infection
Qa-1 限制性肽在稳态和病毒感染期间的呈现
基本信息
- 批准号:10379603
- 负责人:
- 金额:$ 4.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AffinityAgonistAminopeptidaseCD8-Positive T-LymphocytesCellsCharacteristicsCytomegalovirusDataFamilyGenerationsHIV vaccineHomeostasisImmuneInfectionLeadLigandsLightMouse StrainsMusNatural Killer CellsPeptide/MHC ComplexPeptidesPlayPrincipal InvestigatorProteinsQa-1 AntigenSignal TransductionT cell responseT-LymphocyteTestingThymus GlandTissuesTransgenic MiceVaccine DesignVirus Diseasesantigen processingbasecell typeimmunoregulationin vivointerestmemberpathogenprogramsreceptorvector
项目摘要
Program Director/Principal Investigator (Robey, Ellen, A):
Abstract:
Mouse Qa-1 is a member of the conserved MHC-E family of non-classical MHC-1 molecules (MHC1b). In
most cells, MHC-E presents peptides derived from the leader sequences of classical (MHC1a) molecules, and
regulates the function of NK cells through the receptors NKG2A and NKG2C. MHC-E molecules can also
present self and pathogen derived peptides to CD8 T cells. The signals that lead to presentation of alternative
peptides by MHC-E, and the functions of the responding CD8 T cells remain poorly understood. Recently,
studies of a highly effective HIV vaccine based on a CMV vector revealed a prominent MHC-E restricted CD8
T cell response, raising new interest in understanding the presentation mechanisms and in vivo functions of
MHC-E.
Together with our collaborators, we have been investigating a Qa-1-restricted T cell response to cells
lacking the ER aminopeptidase associated with antigen processing (ERAAP ko) {Nagarajan:2012cn}. The
responding CD8 T cells recognize a 9-mer peptide derived from a self-protein (FL9 from FAM49B) presented
by Qa-1(b) (called QFL T cells). QFL T cells use a semi-invariant TCR alpha chain, and have characteristics of
both conventional and non-conventional CD8 T cells. Our preliminary data indicate that QFL T cells encounter
high affinity Qa-1 restricted ligands at steady state and during viral infection. We propose to use a newly
generated TCR transgenic mouse strain to probe the in vivo generation of Qa-1 restricted ligands for QFL T
cells in both steady state and during viral infection. In Aim 1, we will identify the pMHC ligands involved in
positive and agonist selection of QFL T cells, and will identify the thymic cell types that present the ligands. In
Aim 2, we will identify the ligand(s) that drive the homeostatic expansion of QFL T cells, and will determine
when, in what tissue, and by what cell type(s) they are presented. In Aim 3, we will determine the mechanisms
that lead to priming of QFL T cells during MCMV infection, and will test whether QFL T cells induced during
MCMV infection can kill infected cells and provide immune protection.
Our results will shed new light on how MHC-E presentation regulates T cell responses, with important
implications for vaccine design.
OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format Page
项目主任/首席调查员(罗比,艾伦,A):
摘要:
小鼠Qa-1是非经典MHC-1分子(MHC1b)中保守的MHC-E家族成员。在……里面
大多数细胞,MHC-E提供源自经典(MHC1a)分子的前导序列的肽,以及
通过受体NKG2A和NKG2C调节NK细胞的功能。MHC-E分子也可以
将自身和病原体来源的多肽呈递给CD8T细胞。导致提出替代方案的信号
MHC-E的多肽以及应答的CD8T细胞的功能仍然知之甚少。最近,
基于CMV载体的高效HIV疫苗的研究揭示了MHC-E限制的CD8
T细胞反应,引起了人们对理解T细胞递呈机制和体内功能的新兴趣
MHC-E
与我们的合作者一起,我们一直在研究Qa-1限制的T细胞对细胞的反应
缺乏与抗原处理相关的ER氨基肽酶(ERAAP Ko)[Nagarajan:2012cn}。这个
反应性CD8 T细胞识别来自自身蛋白(FAM49B的Fl9)的9肽
Qa-1(B)(称为QFL T细胞)。QFL T细胞使用半不变的TCRα链,并具有以下特征
包括常规和非常规CD8T细胞。我们的初步数据表明QFL T细胞遇到
稳定状态和病毒感染期间的高亲和力Qa-1限制性配体。我们建议使用一种新的
构建TCR转基因小鼠品系探索Qa-1限制性QFL T配体的体内生成
处于稳定状态和病毒感染期间的细胞。在目标1中,我们将确定参与的pMHC配体
QFL T细胞的阳性和激动剂选择,并将识别呈现配体的胸腺细胞类型。在……里面
目的2,我们将确定驱动QFL T细胞动态平衡扩张的配体(S),并将确定
它们何时、在什么组织中、由什么细胞类型(S)呈现。在目标3中,我们将确定机制
这将导致MCMV感染期间QFL T细胞的启动,并将测试QFL T细胞在感染MCMV期间是否诱导
MCMV感染可以杀死被感染的细胞,并提供免疫保护。
我们的结果将为MHC-E如何调节T细胞反应提供新的线索,具有重要的意义
对疫苗设计的影响。
OMB编号0925-0001/0002(01/18修订版批准至2020年3月31日)页面续格式页面
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURENT COSCOY其他文献
LAURENT COSCOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURENT COSCOY', 18)}}的其他基金
Presentation of Qa-1 restricted peptides during homeostasis and viral infection
Qa-1 限制性肽在稳态和病毒感染期间的呈现
- 批准号:
10591419 - 财政年份:2020
- 资助金额:
$ 4.97万 - 项目类别:
Presentation of Qa-1 restricted peptides during homeostasis and viral infection
Qa-1 限制性肽在稳态和病毒感染期间的呈现
- 批准号:
10542654 - 财政年份:2020
- 资助金额:
$ 4.97万 - 项目类别:
Presentation of Qa-1 restricted peptides during homeostasis and viral infection
Qa-1 限制性肽在稳态和病毒感染期间的呈现
- 批准号:
10369722 - 财政年份:2020
- 资助金额:
$ 4.97万 - 项目类别:
Title: Role of Heparan sulfate in B-cell responses
标题:硫酸乙酰肝素在 B 细胞反应中的作用
- 批准号:
8501350 - 财政年份:2012
- 资助金额:
$ 4.97万 - 项目类别:
Title: Role of Heparan sulfate in B-cell responses
标题:硫酸乙酰肝素在 B 细胞反应中的作用
- 批准号:
8385106 - 财政年份:2012
- 资助金额:
$ 4.97万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 4.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 4.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 4.97万 - 项目类别: